- Home
- ALPS vs VTVT Comparison
ALPS vs VTVT Comparison
Compare ALPS & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALPS | VTVT |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.7M | 143.7M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ALPS | VTVT |
|---|---|---|
| Price | $0.98 | $38.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $53.00 |
| AVG Volume (30 Days) | 13.1K | ★ 39.4K |
| Earning Date | 07-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $14.00 |
| 52 Week High | $1.72 | $44.00 |
Technical Indicators
Market Signals| Indicator | ALPS | VTVT |
|---|---|---|
| Relative Strength Index (RSI) | 48.59 | 52.35 |
| Support Level | $0.85 | $33.91 |
| Resistance Level | $1.02 | $42.12 |
| Average True Range (ATR) | 0.06 | 2.63 |
| MACD | -0.01 | -0.19 |
| Stochastic Oscillator | 45.45 | 39.50 |
Price Performance
Historical ComparisonAbout ALPS ALPS Group Inc Ordinary Share
ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential novel first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. The group and its development partners are investigating multiple molecules across different indications for chronic diseases. Its product pipeline are HPP737, Azeliragon, TTP-RA, TTP273, HPP971 / HPP3033, and HPP593.